Mark E. Bunnage

CIK: 0002100735

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (50.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)1 (10.0%)

Compensation grants

Other (G, F, J, C, D, …)4 (40.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VRTX

VERTEX PHARMACEUTICALS INC / MA

Officer

Discretionary Trading P&L

Holdings

Transaction History (10 total)

VRTX
VERTEX PHARMACEUTICALS INC / MA
May 15, 2026
Sale(S)
Direct
33 shares at avg. $453.45$15K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 25, 2026
Sale(S)
Direct
620 shares at avg. $486.35$302K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 24, 2026
Tax Payment(F)
Direct
582 shares at avg. $485.11$282K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 18, 2026
Sale(S)
Direct
1.2K shares at avg. $473.68$560K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 17, 2026
Award(A)
Direct
2.6K shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 17, 2026
Tax Payment(F)
Direct
1.1K shares at avg. $483.75$537K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 17, 2026
Sale(S)
Direct
2.4K shares at avg. $489.46$1.2M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 13, 2026
Tax Payment(F)
Direct
2.3K shares at avg. $487.76$1.1M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 11, 2026
Sale(S)
Direct
2K shares at avg. $460.43$931K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 10, 2026
Tax Payment(F)
Direct
1.1K shares at avg. $468.41$528K

		Type	Shares	Price		Ownership
May 15, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	33	$453.45	$14,964	Direct
Feb 25, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	620	$486.35	$301,537	Direct
Feb 24, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Tax Payment(F)	582	$485.11	$282,334	Direct
Feb 18, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	1,182	$473.68	$559,890	Direct
Feb 17, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A)	2,584	-	$0	Direct
Feb 17, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Tax Payment(F)	1,110	$483.75	$536,963	Direct
Feb 17, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	2,437	$489.46	$1,192,814	Direct
Feb 13, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Tax Payment(F)	2,283	$487.76	$1,113,556	Direct
Feb 11, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	2,021	$460.43	$930,529	Direct
Feb 10, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Tax Payment(F)	1,127	$468.41	$527,898	Direct

1-10 of 10 transactions

About Bunnage Mark E.

Bunnage Mark E. (SEC CIK 0002100735) files insider reports with the SEC as EVP, Chief Scientific Officer of VERTEX PHARMACEUTICALS INC / MA (VRTX).

Signal8 holds 6 ownership filings by Bunnage Mark E. (1 Form 3, 5 Form 4), filed between Feb 3, 2026 and May 19, 2026. Those filings report 10 transactions, from Feb 10, 2026 to May 15, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Bunnage Mark E.'s filings is in BOSTON, MA.

Recent filings by Bunnage Mark E.

May 15, 2026: Open-market sale of VRTX shares (Form 4, code S).
Feb 25, 2026: Open-market sale of VRTX shares (Form 4, code S).
Feb 24, 2026: Tax withholding of VRTX shares (Form 4, code F).
Feb 18, 2026: Open-market sale of VRTX shares (Form 4, code S).
Feb 17, 2026: Grant or award of VRTX shares (Form 4, code A).

Other insiders filing for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Brennan Daniel J., Director
SACHS BRUCE I, Director
Garber Alan M, Director
van Grunsven Jasper, EVP, CP and NPPO
Ambrose Kristen, SVP & Chief Accounting Officer
Tatsis Ourania, EVP, Chief Reg. & Quality Off.

How to read Form 4 transaction codes